Gal9/TIM-3 Expression Levels Affects Chemotherapy in Leukemia Patients
A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia.
The Role of 4-GES Gene Expression Signatures in AML Prognostics
Can Patient-Derived Xenografts Predict Treatment Responses in Glioblastoma?
A new study offers hope in predicting glioblastoma responses to chemotherapy, radiation, and combination therapy.
Biopsies May Help Guide Treatment for Bladder Cancer
A new study found a biopsy of a single metastasis may be enough to help oncologists tailor a treatment that targets all of a patient’s tumors.
CX-01 Heparin Derivative Investigated for Older Patients With AML
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.
Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AML
Early data on the safety and tolerability of combination venetoclax and cytarabine or cytarabine/idarubicin were presented at ASCO 2019.
A Breakthrough Treatment With Enfortumab for Metastatic Urothelial Cancer
A new agent that targets Nectin-4, a protein found in 97% of urothelial cancers, may be an option for patients with locally advanced or metastatic forms of urothelial cancer.
Is It Time to Change Clinical Trial Inclusion Criteria in Lung Cancer?
It may be possible to double the number of patients eligible for clinical trials for advanced lung cancer by expanding trial eligibility criteria based on new technologies and advances in supportive care.
Sexual Harassment, Gender Inequalities Reportedly Common Among Gynecologic Oncologists
The results come from a survey administered to physician members of the Society of Gynecologic Oncology.
Comparing Laparoscopic vs Open Surgery for Colorectal Liver Metastases
Data from the randomized OSLO-COMET trial were presented at ASCO 2019, revealing the survival of laparoscopic vs open surgery for liver metastases in colorectal cancer.
ACA May Impact Ovarian Cancer Outcomes
In this study from Johns Hopkins, it was found that women with ovarian cancer had better outcomes after the implementation of the Affordable Care Act.
‘Practice-Changing’ Results Seen With Enzalutamide in Men With Hormone-Sensitive Prostate Cancer
The phase III ENZAMET study showed 'practice-changing' results with enzalutamide for men with metastatic hormone-sensitive prostate cancer.
Medicaid Expansion Improved Racial Disparities in Cancer Care
Researchers are reporting that previous racial disparities in timely cancer treatment between African American and white patients practically disappeared in states where Medicaid access was expanded under the ACA.
Location and Insurance Matter When It Comes to Survival in Multiple Myeloma
Research presented at ASCO 2019 posited that multiple socioeconomic factors make a real difference in overall survival.
Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer
The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer.
Pembrolizumab May Be an Alternative to Chemo for Select Patients With Gastric Cancers
Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.
Does Pembrolizumab Extend Survival in Patients with NSCLC?
Researchers reported the latest data from the phase Ib KEYNOTE-001 clinical trial at ASCO 2019.
Mutation Profiles May Aid in Treatment of Non–Clear-Cell Renal Cell Carcinoma
Analyzing somatic and germline mutations and MSI may reveal clinically actionable mutations in a proportion of patients with advanced RCC.
Enasidenib: A Promising Option for IDH2-Mutated Acute Myeloid Leukemia?
The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML.
Study Adds Evidence on The Link Between Leukemia Cutis and Poor Prognosis in AML
A recent study in JAMA Dermatology evaluated overall and leukemia-specific survival in patients with AML and leukemia cutis vs AML alone.
High-Dose Vitamin D3 May Be Beneficial in Patients with Metastatic CRC
A study in JAMA evaluated whether adding high-dose vitamin D3 to standard chemotherapy improves PFS in patients with advanced or metastatic colorectal cancer.
Nonoperative Management May Be Possible for Select Patients With Rectal Cancer
Researchers evaluated a “watch and wait” strategy that includes chemotherapy and radiation, but not surgery, in carefully selected patients with rectal cancer.
Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AML
Researchers are evaluating Iodine (131I) apamistamab plus HCT vs conventional care in older patients with active relapsed/refractory acute myeloid leukemia.
Venetoclax Plus LDAC May Benefit Patients with AML Ineligible for Intensive Chemotherapy
A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia.
Cabozanitinib Shows Anti-Tumor Activity Beyond Clear-Cell Renal Cell Carcinoma
A recent study in The Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC.
Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined
A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.
Liquid vs Tissue Biopsy in Detecting Biomarkers for Advanced NSCLC
Researchers' findings on the efficacy of a liquid biopsy test called Guardant360 vs standard tissue biopsies will be presented at AACR 2019.
Experimental Vaccines in Development for Relapsing Patients With AML
Although many immunotherapies for AML have been explored, none have ever been shown to reduced relapse rates.
JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC
Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma.
Certain Factors Impact Treatment Selection in Advanced Prostate Cancer
Do race, income level, geographic location, and type of specialist influence treatment of metastatic castration-resistant prostate cancer?